Health Condition 1: G63- Polyneuropathy in diseases classified elsewhere
Conditions
Interventions
Intervention1: Lacosamide: Lacosamide
50mg BD , oral, initially for 1 week followed by
100mg BD,oral, for 3 months
Control Intervention1: Pregabalin: Pregabalin
75mg OD , Oral for 3 months
Sponsors
SRM College of Pharmacy
Eligibility
Inclusion criteria
Inclusion criteria: Patients with definite or probable neuropathic pain for more than 3 months. Patients who are willing to give informed consent
Exclusion criteria
Exclusion criteria: Patient with concomitant pain syndrome that could affect the pain evaluation such fibromyalgia. Patients with serious concurrent systemic disease such as liver problems, severe renal impairment, malignancy. Patients with a history of cardiac arrhythmias or taking antiarrhythmic drugs Patients with a resting heart rate of less than 55 beats/min or greater than 100 beats/min on electrocardiogram (ECG) screening Patients on concomitant treatment with antidepressants, other anticonvulsants and opioids that could not be discontinued. Pregnant women and lactating mothers. Drug-induced neuropathic pain. Patients who are not willing to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The individual change in NRS indicating analgesic effect of lacosamideTimepoint: Every 2 weeks after the drug administration. | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in the pain score between lacosamide and pregabalin along with evaluation of quality of life of patients and safety assessment of lacosamide for clinical use in neuropathic pain patients. Timepoint: Towards the end of the study. | — |
Countries
India
Contacts
Public ContactMs Fatema Juzer Haji
SRM College of Pharmacy
Outcome results
None listed